A novel mouse model for de novo melanoma (Cancer Research (2010) 70, (24-9) DOI: 10.1158/0008-5472.CAN-09-2838);A novel mouse model for de novo melanoma

Cancer Research

Volumn 70, Issue 1, 2010, Pages 24-29

  Kumasaka, Mayuko Y ^a   Yajima, Ichiro ^a   Hossain, Khaled ^a   Iida, Machiko ^a   Tsuzuki, Toyonori ^b   Ohno, Tamio ^b   Takahashi, Masahide ^b   Yanagisawa, Masashi ^c   Kato, Masashi ^a  

^a CHUBU UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CARCINOGENESIS; DE NOVO MELANOMA; HISTOPATHOLOGY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 75149129051     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0036     Document Type: Erratum

References (19)

1. Chiang JM, Wu Chou YH, Ma SC, Chen JR. Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes. Virchows Arch 2004;445:465-71.
2. Olschwang S, Hamelin R, Laurent-Puig P, et al. Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A 1997;94:12122-7.
3. Hede SM, Hansson I, Afink GB, et al. GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. Glia 2008;57:1143-53.
4. Zhu H, Acquaviva J, Ramachandran P, et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A 2009;106:2712-6.
5. Kaddu S, Smolle J, Zenahlik P, Hofmann-Wellenhof R, Kerl H. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res 2002; 12:271-8.
6. Friedman RJ, Rigel DS, Kopf AW, et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol 1983;119:455-62.
7. Weatherhead SC, Haniffa M, Lawrence CM. Melanomas arising from naevi and de novo melanomas-does origin matter? Br J Dermatol 2007;156:72-6.
8. Kato M, Takahashi M, Akhand AA, et al. Transgenic mouse model for skin malignant melanoma. Oncogene 1998;17:1885-8.
9. Kato M, Takeda K, Kawamoto Y, et al. c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res 2004;64: 801-6.
10. Kato M, Liu W, Yi H, et al. The herbal medicine Sho-saiko-to inhibits growth and metastasis of malignant melanoma primarily developed in ret-transgenic mice. J Invest Dermatol 1998;111:640-4.
11. Hosoda K, Hammer RE, Richardson JA, et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 1994; 79:1267-76.
12. Yajima I, Kumasaka M, Thang ND, et al. Zinc finger protein 28 as a novel melanoma-related molecule. J Dermatol Sci 2009;55:68-70.
13. Genis L, Galvez BG, Gonzalo P, Arroyo AG. MT1-MMP: universal or particular player in angiogenesis? Cancer Metastasis Rev 2006;25: 77-86.
14. Watson-Hurst K, Becker D. The role of N-cadherin, MCAM and β3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 2006;5:1375-82.
15. Perlis C, Herlyn M. Recent advances in melanoma biology. Oncologist 2004;9:182-7.
16. Mills L, Tellez C, Huang S, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002;62:5106-14.
17. Soufir N, Meziani R, Lacapere JJ, et al. Association between endothelin receptor B nonsynonymous variants and melanoma risk. J Natl Cancer Inst 2005;97:1297-301.
18. Lahav R, Suva ML, Rimoldi D, Patterson PH, Stamenkovic I. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res 2004;64:8945-53.
19. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A 1999;96:11496-500.